18 Results for "

point mutation

" in MedChemExpress (MCE) Product Catalog:
Products (18)

18 Results for "point mutation" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P99033
CAS No.: 1905409-39-3
Synonyms: BTCT-4465A; RG-7828; RO7030816
Target:  

CD20 CD3

Research Areas:  

Cancer

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions .
loading...
    loading...
Cat. No.: HY-Y1010
CAS No.: 556-52-5
Synonyms: Glycidol
Target:  

Drug Isomer

Research Areas:  

Cancer

Oxiran-2-ylmethanol (Glycidol) is an ester product. Oxiran-2-ylmethanol induces base pair point mutations in bacterial strains and structural chromosome aberrations in cultured cells. Oxiran-2-ylmethanol forms N-(2,3-dihydroxypropyl)valine hemoglobin adducts. Oxiran-2-ylmethanol acts as an animal carcinogen but does not significantly induce micronucleated immature erythrocytes in animal bone marrow. Oxiran-2-ylmethanol enables anionic polymerization to produce linear poly(glycidol). Oxiran-2-ylmethanol can be used for cancer-related research .
loading...
    loading...
Cat. No.: HY-153736
CAS No.: 90379-42-3
Purity:  98.40%
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

NSC 194308, a U2AF2-RNA complexes enhancer, increases association of the U2AF1-U2AF2-SF1-splice site RNA complex by binding a site between the U2AF2 RNA recognition motifs (RRM1 and RRM2). NSC 194308 inhibits pre-mRNA splicing by stalling spliceosome assembly at the point where U2AF helps recruit U2 snRNP to the branchpoint. NSC 194308 enhances the binding of pre-mRNA to U2AF2, selectively triggering cell death in leukemia cell lines containing spliceosome mutations .
loading...
    loading...
Cat. No.: HY-P991223

Research Areas:  

Cancer

NC762 is a humanized IgG1κ monoclonal antibody that targets human B7-H4 (B7 homolog 4). NC762 has enhanced binding to CD16a (FcγRIIIa) after being Fc engineered with three point mutations (S239D/A330L/I332E; DLE) and demonstrate increased antibody-dependent cellular cytotoxicity (ADCC) activity. NC762 inhibits tumor growth in vivo through binding to tumor-expressing B7-H4. NC762 can be studies in research on cancer such as advanced or metastatic solid tumors .
loading...
    loading...
Cat. No.: HY-P10610A
Target:  

MDM-2/p53

Research Areas:  

Cancer

Peptide 234CM TFA is a peptide containing isoleucine at position 3, corresponding to the sequence of a point mutation in p53 codon 234. Peptide 234CM TFA induces potent cytotoxic T cell (CTL) and antitumor immune responses against mutant p53 .
loading...
    loading...
Cat. No.: HY-105740
CAS No.: 68-76-8
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Trenimon is a compound with anti-cancer effects. Trenimon shows mutagenic actions in many species by inducing point and chromosomal mutations, sister-chromatid exchanges, recombination phenomena and phage induction. Trenimon can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-P10610
CAS No.: 155314-25-3
Target:  

MDM-2/p53

Research Areas:  

Cancer

Peptide 234CM is a peptide containing isoleucine at position 3, corresponding to the sequence of a point mutation in p53 codon 234. Peptide 234CM induces potent cytotoxic T cell (CTL) and antitumor immune responses against mutant p53 .
loading...
    loading...
Cat. No.: HY-178938
CAS No.: 1182011-65-9
AR Degrader-3 is an orally active molecular glue that targets AR/ARV7 and induces the degradation of AR and ARV7 through the ubiquitin-proteasome pathway (UPP). AR Degrader-3 directly interacts with the ligand-binding domain (LBD) and the N-terminal domain (NTD) of AR. AR Degrader-3 effectively suppresses the transcriptional activity of wild-type AR (AR-WT), AR mutants, and ARV7. AR Degrader-3 downregulates the mRNA and protein levels of downstream AR target genes, thereby overcoming antiandrogen resistance mediated by ARV7 and AR point mutations. AR Degrader-3 induces apoptosis in Enzalutamide (HY-70002) (ENZa)-resistant cells and increases cleaved caspase-3 protein levels. AR Degrader-3 can be used for the study of castration-resistant prostate cancer (CRPC) .
loading...
    loading...
Cat. No.: HY-P5986
Target:  

ERK

Research Areas:  

Others

mSIRK (L9A) is a cell-permeable, N-myristoylated G-Protein Binding Peptide (mSIRK). mSIRK (L9A) contains a single point mutation (Leu9 to Ala). mSIRK (L9A) cannot enhance ERK1/2 phosphorylation. mSIRK (L9A) can be used as a control peptide .
loading...
    loading...
Cat. No.: HY-143616
CAS No.: 2659225-28-0
Research Areas:  

Cancer

EZH2-IN-7 is a potent inhibitor of EZH2. EZH2 overexpression or mutations in the SET region (Y641F, Y641N, A687V, A677G point mutations) all lead to abnormal elevation of H3K27me3 and promote the growth and development of many types of tumors, such as breast cancer, prostate cancer, leukemia, etc. EZH2-IN-7 has the potential for the research of cancer diseases (extracted from patent WO2021129629A1, compound 259) .
loading...
    loading...
Cat. No.: HY-123201
CAS No.: 919767-02-5
Target:  

FLT3

Research Areas:  

Cancer

KRN383 analog is an analog of KRN383. KRN383 is an orally active Flt3 inhibitor that inhibits the autophosphorylation of Flt3 bearing internal tandem duplications (ITDs) and the Asp835Tyr (D835Y) point mutation with IC50 values of < or =5.9 and 43 nM, respectively. KRN383 also inhibits the proliferation of the ITD-positive cell lines with IC50 values of < or =2.9 nM. KRN383 can be used for the research of acute myeloid leukemia .
loading...
    loading...
Cat. No.: HY-P2307
CAS No.: 847829-41-8
Target:  

iGluR NO Synthase

Research Areas:  

Neurological Disease

Tat-NR2BAA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .
loading...
    loading...
Cat. No.: HY-P2307A
Target:  

iGluR NO Synthase

Research Areas:  

Neurological Disease

Tat-NR2BAA TFA is the control peptide of Tat-NR2B9c (HY-P0117), inactive. The sequence of Tat-NR2BAA TFA is similar to Tat-NR2B9c, but it has a double-point mutation in the COOH terminal tSXV motif, making it incapable of binding PSD-95. Tat-NR2B9c is a membrane-permeant peptide and disrupts PSD-95/NMDAR binding, correlate with uncoupling NR2B- and/or NR2A-type NMDARs from PSD-95 .
loading...
    loading...
Cat. No.: HY-Y1010S
CAS No.: 1246819-20-4
Synonyms: Glycidol-d5
Oxiran-2-ylmethanol-d5 is the deuterium labeled Oxiran-2-ylmethanol (Glycidol) (HY-Y1010). Oxiran-2-ylmethanol is an ester product. Oxiran-2-ylmethanol induces base pair point mutations in bacterial strains and structural chromosome aberrations in cultured cells. Oxiran-2-ylmethanol forms N-(2,3-dihydroxypropyl)valine hemoglobin adducts. Oxiran-2-ylmethanol acts as an animal carcinogen but does not significantly induce micronucleated immature erythrocytes in animal bone marrow. Oxiran-2-ylmethanol enables anionic polymerization to produce linear poly(glycidol). Oxiran-2-ylmethanol can be used for cancer-related research .
loading...
    loading...
Cat. No.: HY-Y1010R
CAS No.: 556-52-5
Synonyms: Glycidol (Standard)
Research Areas:  

Cancer

Oxiran-2-ylmethanol (Standard) is the analytical standard of Oxiran-2-ylmethanol (Glycidol) (HY-Y1010). This product is intended for research and analytical applications. Oxiran-2-ylmethanol is an ester product. Oxiran-2-ylmethanol induces base pair point mutations in bacterial strains and structural chromosome aberrations in cultured cells. Oxiran-2-ylmethanol forms N-(2,3-dihydroxypropyl)valine hemoglobin adducts. Oxiran-2-ylmethanol acts as an animal carcinogen but does not significantly induce micronucleated immature erythrocytes in animal bone marrow. Oxiran-2-ylmethanol enables anionic polymerization to produce linear poly(glycidol). Oxiran-2-ylmethanol can be used for cancer-related research .
loading...
    loading...
Cat. No.: HY-101977A
CAS No.: 2097002-59-8
Synonyms: (R,S)-LOXO-195
Target:  

Trk Receptor

Research Areas:  

Cancer

(R,S)-Selitrectinib ((R,S)-LOXO-195) (compound 17) is a Trk inhibitor with activity against cancers harboring Trk inhibitor-resistant point mutations in NTRK1, NTRK2, or NTRK3 genes. (R,S)-Selitrectinib can be used for the research of trk inhibitor-resistant cancer .
loading...
    loading...
Cat. No.: HY-E70894
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease

α,γ-Homocysteinase, Trichomonas vaginalis is a pyridoxal-5’-phosphate dependent enzyme. α,γ-Homocysteinase, Trichomonas vaginalis is a mutant of homocysteinase from Trichomonas vaginalis encoded by mgl1 gene, containing three point mutations, such as; Phe47Leu, Asp172Glu, Ser308Tyr. α,γ-Homocysteinase, Trichomonas vaginalis can metabolize homocysteine into α-keto butyrate, hydrogen sulfide and ammonia.
loading...
    loading...
Cat. No.: HY-P991839

Target:  

CD19

Research Areas:  

Cancer

Anti-CD19 Antibody (FMC63) is an antibody that binds to CD19, with a human Kd value ranging from 0.42 nM to 149 nM. Anti-CD19 Antibody (FMC63) mediates tumor cell killing, cytokine secretion, stable CAR expression, T cell activation and memory differentiation. Anti-CD19 Antibody (FMC63) fails to eliminate lymphoma cells carrying CD19 point mutations or co-expressing FMC63-CAR19, induces higher levels of activation-induced cell death, and reduces cell persistence. Anti-CD19 Antibody (FMC63) can be used in research related to B-cell non-Hodgkin's lymphoma, B-cell acute lymphoblastic leukemia, relapsed or refractory diffuse large B-cell lymphoma, etc .
loading...
    loading...
  • 1